Table 5.
Diagnostic value of biomarker levels for axSpA
| AxSpA vs women with postpartum pain | AxSpA vs disc herniation patients | AxSpA vs healthy controls | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUROC [95% CI] | T | S | SP | AUROC [95% CI] | T | S | SP | AUROC [95% CI] | T | S | SP | |
| C1M | 0.66 [0.50–0.82] | 66.2 | 0.96 | 0.43 | 0.59 [0.40–0.78] | 67.8 | 0.92 | 0.43 | 0.73 [0.61–0.86] | 72.7 | 0.98 | 0.43 |
| C2M | 0.41 [0.24–0.58] | 18.2 | 0.25 | 0.87 | 0.38 [0.18–0.58] | 35.2 | 1.00 | 0.043 | 0.56 [0.42–0.70] | 19.8 | 0.44 | 0.78 |
| T2CM | 0.60 [0.43–0.77] | 5.4 | 0.71 | 0.61 | 0.51 [0.30–0.72] | 5.6 | 0.75 | 0.48 | 0.56 [0.42–0.70] | 5.4 | 0.65 | 0.61 |
| C3M | 0.50 [0.32–0.68] | 18.1 | 1.00 | 0.26 | 0.45 [0.25–0.66] | 15.9 | 0.75 | 0.35 | 0.54 [0.39–0.69] | 20.1 | 0.98 | 0.22 |
| C4M | 0.65 [0.47–0.82] | 33.9 | 0.92 | 0.57 | 0.57 [0.35–0.78] | 28.1 | 0.67 | 0.61 | 0.68 [0.54–0.82] | 33.7 | 0.81 | 0.57 |
| C6M | 0.68 [0.51–0.84] | 19.6 | 0.88 | 0.57 | 0.47 [0.27–0.68] | 23.1 | 0.75 | 0.35 | 0.73 [0.59−0.87] | 19.4 | 0.90 | 0.57 |
| C10C | 0.42 [0.25–0.59] | 2924.8 | 0.88 | 0.22 | 0.49 [0.28–0.70] | 1698.7 | 0.083 | 1.00 | 0.61 [0.47–0.75] | 2332 | 0.54 | 0.70 |
| COL10NC | 0.45 [0.28–0.62] | 13.7 | 0.96 | 0.22 | 0.50 [0.29–0.72] | 13.5 | 0.92 | 0.22 | 0.36 [0.21–0.51] | 16.4 | 0.96 | 0.13 |
| PROM | 0.75 [0.61−0.89] | 0.27 | 0.83 | 0.65 | 0.59 [0.40–0.79] | 0.34 | 0.92 | 0.43 | 0.69 [0.56−0.82] | 0.34 | 0.91 | 0.43 |
| VICM | 0.77 [0.63−0.91] | 3.6 | 0.79 | 0.70 | 0.68 [0.48–0.89] | 2.6 | 0.58 | 0.83 | 0.72 [0.58−0.85] | 3.0 | 0.59 | 0.78 |
| CRPM | 0.65 [0.49–0.81] | 11.1 | 0.75 | 0.57 | 0.58 [0.37–0.80] | 11.5 | 0.75 | 0.52 | 0.62 [0.47–0.77] | 11.7 | 0.75 | 0.52 |
| PRO-C2 | 0.43 [0.26–0.60] | 21.6 | 0.50 | 0.57 | 0.54 [0.31–0.78] | 16.7 | 0.42 | 0.91 | 0.47 [0.33–0.61] | 16.7 | 0.15 | 0.91 |
| PRO-C3 | 0.48 [0.31–0.65] | 10.8 | 0.67 | 0.43 | 0.39 [0.20–0.58] | 11.5 | 0.75 | 0.3 | 0.36 [0.21–0.50] | 18.1 | 0.98 | 0.043 |
| PRO-C4 | 0.75 [0.61−0.89] | 7227 | 0.79 | 0.65 | 0.59 [0.39–0.80] | 7575.1 | 0.83 | 0.43 | 0.82 [0.73−0.92] | 7224.1 | 0.88 | 0.65 |
| PRO-C6 | 0.39 [0.22–0.55] | 10.1 | 0.92 | 0.13 | 0.45 [0.23–0.66] | 12.5 | 1.00 | 0.087 | 0.60 [0.45–0.74] | 5.1 | 0.31 | 0.91 |
| C2M/PRO-C2 | 0.46 [0.28–0.63] | 0.54 | 0.12 | 1.00 | 0.43 [0.20–0.66] | 0.91 | 0.42 | 0.74 | 0.56 [0.41–0.70] | 1.1 | 0.65 | 0.57 |
| C3M/PRO-C3 | 0.53 [0.36–0.71] | 2.2 | 1.00 | 0.22 | 0.49 [0.28–0.70] | 2.3 | 1.00 | 0.22 | 0.61 [0.46–0.75] | 1.2 | 0.48 | 0.74 |
| C4M/PRO-C4 | 0.53 [0.35–0.72] | 0.004 | 0.75 | 0.52 | 0.56 [0.36–0.77] | 0.0052 | 0.92 | 0.35 | 0.53 [0.36–0.69] | 0.005 | 0.85 | 0.39 |
| C6M/PRO-C6 | 0.71 [0.56–0.86] | 3.0 | 0.79 | 0.61 | 0.56 [0.35–0.77] | 2.5 | 0.42 | 0.78 | 0.61 [0.47–0.76] | 3.1 | 0.73 | 0.57 |
| CRP | 0.80 [0.67–0.93] | 1.9 | 0.88 | 0.61 | 0.71 [0.54–0.88] | 2.5 | 0.83 | 0.57 | 0.83 [0.73–0.93] | 1.8 | 0.85 | 0.65 |
The analyses were performed using AUROC, and threshold, sensitivity and specificity are provided. AUC that had statistical significance of p < 0.001 are highlighted in bold
Abbreviations: AUROC area under receiver operator characteristics curve, T threshold (ng/ml), S sensitivity, SP specificity, CI confidence interval, C1M metalloproteinase (MMP)-degraded type I collagen, C2M metalloproteinase (MMP)-degraded type II collagen, T2CM MMP-1 and MMP-13-mediated degradation of type II collagen, C3M MMP-degraded type III collagen, C4M MMP-degraded type IV collagen, C6M MMP-degraded type VI collagen, C10C cathepsin-K-mediated degradation of type X collagen, COL10NC NC domain of type X collagen, PROM MMP-1 and MMP-13-mediated degradation of prolargin, VICM citrullinated and MMP-degraded vimentin, CRPM C-reactive protein metabolite, CRP C reactive protein, PRO-C2 pro-peptide of type II collagen, PRO-C3 pro-peptide of type III collagen, PRO-C4 pro-peptide of type IV collagen, PRO-C6 pro-peptide of type VI collagen